Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)’s iron deficiency product Accrufer has had its shelf life extended from 36 months to 48 months following approval from the US Food and Drug Administration (FDA).
The London-listed commercial-stage pharmaceutical company has now doubled the shelf life of its lead product over the past year.
Chief executive officer Greg Madison stated: "Not only does this confirm the stable and robust nature of the capsule formulation of Accrufer®, but also provides additional supply-chain flexibility and simplifies global logistics as we continue to support our growing US business and our license partners across the globe."